Status:
COMPLETED
Convalescent Plasma Trial in COVID -19 Patients
Lead Sponsor:
Royal College of Surgeons in Ireland - Medical University of Bahrain
Collaborating Sponsors:
Salmaniya Medical Complex
Bahrain Defence Force Hospital
Conditions:
SARS-CoV 2
COVID-19
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
Plasma therapy using convalescent plasma has been shown to be effective in severe acute respiratory syndrome, Ebola virus infection and in H1N1 influenza. More recently there has been a report of the ...
Detailed Description
Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has developed into a pandemic with serious global public health and economic seque...
Eligibility Criteria
Inclusion
- COVID-19 diagnosis
- Hypoxia, (Oxygen saturation of less than or equal 92% or PO2 \< 60mmHg on arterial blood gas analysis) and patient requiring oxygen therapy
- Evidence of infiltrates on Chest Xray or CT scan
- Able to give informed consent
- Patients between the ages of 21 and above with no upper age.
Exclusion
- Patients with mild disease not requiring oxygen therapy
- Patients with normal CXR \& CT scan
- Patients requiring ventilatory support
- Patients with a history of allergy to plasma, sodium citrate or methylene blue
- Patients with a history of autoimmune disease or selective IGA deficiency.
Key Trial Info
Start Date :
April 19 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 9 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04356534
Start Date
April 19 2020
End Date
July 9 2020
Last Update
October 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal College of Surgeons in Ireland - Bahrain
Manama, Bahrain